Shamburg News · 8-K filed Nov 12, 2026, 4:05 PM EST
ADARx Pharmaceuticals Reports Third Quarter 2026 Results and Business Updates
ADRX · ADARx Pharmaceuticals, Inc.
- Earnings
- Financial statements
- Other event
- Reg FD disclosure
- Materiality: high
ADARx Pharmaceuticals reported financial results for the third quarter ended September 30, 2026, with collaboration revenue of $2.2 million and a net loss of $28.1 million, compared with a net loss of $17.9 million a year earlier. The company said its IPO and concurrent private placement generated aggregate gross proceeds of approximately $602.5 million, and that cash is expected to fund operations into 2030. The release also reported that the FDA granted Fast Track designation to onvuzosiran for HAE in August 2026.
Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, 9.01, accession 0001193125-26-458321.
Written from the filing by Shamburg Markets. Figures are as reported by the company.